Tove Berg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tove Berg has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Janeric Seidegård
AstraZeneca R&D Mölndal Mölndal, Sweden
1 shared publication- Janeric Seidegård
Respiratory, Inflammation and Autoimmunity, IMED Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden
1 shared publication Johan Grunewald
Respiratory Medicine Unit, Department of Medicine Solna and CMM, Karolinska Institutet and Karolinska University Hospital Solna Stockholm, Sweden
1 shared publication- Johan Grunewald
Respiratory Medicine Division, Department of Medicine Solna, and Center for Molecular Medicine (CMM), Karolinska Institutet; and Respiratory Medicine, Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden.
1 shared publication - Johan Öckinger
Neuroimmunology Unit, Department of Clinical Neuroscience, Center of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
1 shared publication Lena Gustavsson
Molecular Medicine, Department of Laboratory Medicine, Lund University Medicon Village, Lund, Sweden
1 shared publication
Latest Publications
- Open Access
- 20 April 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 68
Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals
Several inhaled drugs are dependent on organic cation transporters to cross cell membranes. To further evaluate their potential to impact on inhaled drug disposition, the localization of MATE1, P-gp, OCTN1 and OCTN2 were investigated in human lung. Transporter proteins were analysed by immunohistochemistry in lung tissue from healthy subjects and COPD patients. Transporter mRNA was analysed by qPCR in lung tissue and in bronchoalveolar lavage (BAL) cells from smokers and non-smokers. We demonstrate for the first time MATE1 protein expression in the lung with localization to the apical side of bronchial and bronchiolar epithelial cells. Interestingly, MATE1 was strongly expressed in alveolar macrophages as demonstrated both in lung tissue and in BAL cells, and in inflammatory cells including CD3 positive T cells. P-gp, OCTN1 and OCTN2 were also expressed in the alveolar epithelial cells and in inflammatory cells including alveolar macrophages. In BAL cells from smokers, MATE1 and P-gp mRNA expression was significantly lower compared to cells from non-smokers whereas no difference was observed between COPD patients and healthy subjects. THP-1 cells were evaluated as a model for alveolar macrophages but did not reflect the transporter expression observed in BAL cells. We conclude that MATE1, P-gp, OCTN1 and OCTN2 are expressed in pulmonary lung epithelium, in alveolar macrophages and in other inflammatory cells. This is important to consider in the development of drugs treating pulmonary disease as the transporters may impact drug disposition in the lung and consequently affect pharmacological efficacy and toxicity.
- 20 April 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 68
Open AccessExpression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals
Several inhaled drugs are dependent on organic cation transporters to cross cell membranes. To further evaluate their potential to impact on inhaled drug disposition, the localization of MATE1, P-gp, OCTN1 and OCTN2 were investigated in human lung. Transporter proteins were analysed by immunohistochemistry in lung tissue from healthy subjects and COPD patients. Transporter mRNA was analysed by qPCR in lung tissue and in bronchoalveolar lavage (BAL) cells from smokers and non-smokers. We demonstrate for the first time MATE1 protein expression in the lung with localization to the apical side of bronchial and bronchiolar epithelial cells. Interestingly, MATE1 was strongly expressed in alveolar macrophages as demonstrated both in lung tissue and in BAL cells, and in inflammatory cells including CD3 positive T cells. P-gp, OCTN1 and OCTN2 were also expressed in the alveolar epithelial cells and in inflammatory cells including alveolar macrophages. In BAL cells from smokers, MATE1 and P-gp mRNA expression was significantly lower compared to cells from non-smokers whereas no difference was observed between COPD patients and healthy subjects. THP-1 cells were evaluated as a model for alveolar macrophages but did not reflect the transporter expression observed in BAL cells. We conclude that MATE1, P-gp, OCTN1 and OCTN2 are expressed in pulmonary lung epithelium, in alveolar macrophages and in other inflammatory cells. This is important to consider in the development of drugs treating pulmonary disease as the transporters may impact drug disposition in the lung and consequently affect pharmacological efficacy and toxicity.
- Open Access
- 12 June 2014
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 2 (4) , e00054
Gene expression analysis of membrane transporters and drug‐metabolizing enzymes in the lung of healthy andCOPDsubjects
This study describes for the first time the expression levels of genes encoding membrane transporters and drug‐metabolizing enzymes in the lungs of ex‐smoking patients with chronic obstructive pulmonary disease (COPD). Membrane transporters and drug‐metabolizing enzymes are key determinants of drug uptake, metabolism, and elimination for systemically administered as well as inhaled drugs, with consequent influence on clinical efficacy and patient safety. In this study, while no difference in gene expression was found between healthy and COPD subjects, we identified a significant regional difference inmRNAexpression of both membrane transporters and drug‐metabolizing enzymes between central and peripheral tissue in both healthy and COPD subjects. The majority of the differentially expressed genes were higher expressed in the central airways such as the transportersSLC2A1(GLUT1),SLC28A3(CNT3), andSLC22A4(OCTN1) and the drug‐metabolizing enzymesGSTZ1,GSTO2, andCYP2F1. Together, this increased knowledge of local pharmacokinetics in diseased and normal lung may improve modeling of clinical outcomes of new chemical entities intended for inhalation therapy delivered to COPD patients. In addition, based on the similarities between COPD and healthy subjects regarding gene expression of membrane transporters and drug‐metabolizing enzymes, our results suggest that clinical pharmacological studies in healthy volunteers could be a valid model of COPD patients regarding drug disposition of inhaled drugs in terms of drug metabolism and drug transporters.
- 12 June 2014
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 2 (4) , e00054
Open AccessGene expression analysis of membrane transporters and drug‐metabolizing enzymes in the lung of healthy andCOPDsubjects
This study describes for the first time the expression levels of genes encoding membrane transporters and drug‐metabolizing enzymes in the lungs of ex‐smoking patients with chronic obstructive pulmonary disease (COPD). Membrane transporters and drug‐metabolizing enzymes are key determinants of drug uptake, metabolism, and elimination for systemically administered as well as inhaled drugs, with consequent influence on clinical efficacy and patient safety. In this study, while no difference in gene expression was found between healthy and COPD subjects, we identified a significant regional difference inmRNAexpression of both membrane transporters and drug‐metabolizing enzymes between central and peripheral tissue in both healthy and COPD subjects. The majority of the differentially expressed genes were higher expressed in the central airways such as the transportersSLC2A1(GLUT1),SLC28A3(CNT3), andSLC22A4(OCTN1) and the drug‐metabolizing enzymesGSTZ1,GSTO2, andCYP2F1. Together, this increased knowledge of local pharmacokinetics in diseased and normal lung may improve modeling of clinical outcomes of new chemical entities intended for inhalation therapy delivered to COPD patients. In addition, based on the similarities between COPD and healthy subjects regarding gene expression of membrane transporters and drug‐metabolizing enzymes, our results suggest that clinical pharmacological studies in healthy volunteers could be a valid model of COPD patients regarding drug disposition of inhaled drugs in terms of drug metabolism and drug transporters.